Interstitial Macrophages Lead Early Stages of Bleomycin-Induced Lung Fibrosis and Induce Fibroblasts Activation

Cells. 2023 Jan 24;12(3):402. doi: 10.3390/cells12030402.

Abstract

A progressive fibrosing phenotype is critical in several lung diseases. It is irreversible and associated with early patient mortality. Growing evidence has revealed pulmonary macrophages' role as modulators of the fibrotic processes. The proportion, phenotype, and function of alveolar (AM) and interstitial macrophages (IM) at the early stages of bleomycin-induced pulmonary fibrosis have not been clearly described. In this way, our study aimed to characterize these macrophage populations and investigate the effect on fibroblast activation. C57BL/6 mice were intratracheally injected with bleomycin and were sacrificed at day 3, 5, and 7 for the performance of flow cytometry and fluorescent-activated cell sorting analysis for protein and gene expression quantification. After bleomycin administration, the proportion of IM was significantly higher than that of AM, which showed a decay during the inflammatory phase, and peaked at day 7. At day 7 of the inflammatory phase, AM started shifting their phenotype from M1-like towards M2, while IM showed a M2-like phenotype. Conditioned medium derived from IM sorted at day 7 induced fibroblast activation and differentiation in myofibroblasts in vitro. Our findings indicate that IM are the largest macrophage population at the early stages of experimental pulmonary fibrosis and are secreted mediators able to activate fibroblasts, pointing to macrophage modulation as a potential therapeutic strategy to restrain progressive fibrosing lung disorders.

Keywords: alveolar macrophages; conditioned medium; fibroblasts; interstitial macrophages; myofibroblasts; pulmonary fibrosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bleomycin / pharmacology
  • Fibroblasts / metabolism
  • Macrophages / metabolism
  • Mice
  • Mice, Inbred C57BL
  • Pulmonary Fibrosis* / metabolism

Substances

  • Bleomycin

Grants and funding

This research was funded by the Programa Operacional Potencial Humano (POPH) and Programa Investigador Fundação para a Ciência e Tecnologia (FCT) (IF/00959/2014); by Programa Operacional Fatores de Competitividade (COMPETE) and national funds of FCT (POCI-01-0145-FEDER-028113); and by national funds of FCT (UIDB/50026/2020, UIDP/50026/2020).